Huber Henriette, Edenhofer Simone, Estenfelder Sven, Stilgenbauer Stephan
Department of Internal Medicine III, Ulm University, Ulm, Germany.
Onco Targets Ther. 2017 Feb 7;10:645-656. doi: 10.2147/OTT.S102646. eCollection 2017.
Over the last few years, dramatic changes have occurred in the treatment of chronic lymphocytic leukemia (CLL). The current standard for young and fit patients with CLL remains chemoimmunotherapy, namely the fludarabine, cyclophosphamide, and rituximab (FCR) regimen. However, novel oral therapies are presently being introduced and represent a considerable breakthrough concerning effectiveness and safety profile. In particular, the very high-risk group of CLL patients, defined by the genetic aberration del(17p) and/or mutation, benefit from the new agents. These genetic abnormalities are the most relevant negative prognostic markers in the context of chemoimmunotherapy. New targeted therapies allow different approaches to improve outcomes.
在过去几年中，慢性淋巴细胞白血病（CLL）的治疗发生了巨大变化。对于年轻且身体状况良好的CLL患者，目前的标准治疗方案仍是化疗免疫疗法，即氟达拉滨、环磷酰胺和利妥昔单抗（FCR）方案。然而，新型口服疗法目前正在引入，并且在有效性和安全性方面代表了相当大的突破。特别是，由基因异常del(17p)和/或突变定义的CLL极高危患者群体从这些新药中获益。在化疗免疫疗法的背景下，这些基因异常是最相关的不良预后标志物。新的靶向疗法允许采用不同方法来改善治疗结果。
